Lead Product(s) : Opevesostat,Fludrocortisone Acetate,Glucocorticoid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Product Name : ODM-208
Product Type : Other Small Molecule
Upfront Cash : $290.0 million
July 13, 2022
Lead Product(s) : Opevesostat,Fludrocortisone Acetate,Glucocorticoid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Opevesostat,Fludrocortisone Acetate,Glucocorticoid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
Details : ODM-208 is a novel, oral, non-steroidal and selective inhibitor of CYP11A1 enzyme developed by Orion for the treatment of prostate cancer. ODM-208 suppresses the production of all steroid hormones and their precursors that may activate AR signalling path...
Product Name : ODM-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2022
Lead Product(s) : Opevesostat,Fludrocortisone Acetate,Glucocorticoid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Igrelimogene Litadenorepvec,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : EIC Fund
Deal Size : $25.0 million
Deal Type : Series B Financing
TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing
Details : The financing aims to advance the clinical development of TILT-123 (igrelimogene litadenorepvec), which is being evaluated for the treatment of platinum-resistant epithelial ovarian cancer.
Product Name : TILT-123
Product Type : Microorganism
Upfront Cash : Undisclosed
May 13, 2025
Lead Product(s) : Igrelimogene Litadenorepvec,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : EIC Fund
Deal Size : $25.0 million
Deal Type : Series B Financing
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Faron Posts Positive Phase II Results in High-Risk Myelodysplastic Syndrome
Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastase, being investigated in R/R HR-MDS, in combination with azacitidine.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome
Details : FP-1305 (bexmarilimab), which inhibits the scavenger receptor Clever-1, is being investigated in combination with azacitidine for relapsed/refractory (r/r) HR MDS.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Faron Doses First HMA-failed MDS Patient with Bexmarilimab in BEXMAB Trial
Details : FP-1305 (bexmarilimab), a CLEVER-1 binder, is in Phase 1/2 trials with azacitidine and venetoclax for treating acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
September 01, 2024
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Data from Phase 1 BEXMAB Study in Higher-Risk MDS and r/r AML
Details : FP-1305 (bexmarilimab) is a first-in-class, humanized mAb that binds to Clever-1, an immunosuppressive receptor on macrophages, being evaluated for high-risk myelodysplastic syndrome.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
BEXMAB Data Analysis Provides Insights into HMA-Failed MDS Patient Profiles
Details : FP-1305 (bexmarilimab) is a monoclonal antibody binding to Clever-1, currently in phase 1/2 for treating acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
January 25, 2024
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2023
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
Details : U.S. FDA has granted Orphan Drug Designation to Faron Pharmaceuticals' wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia. ODD will further help bexmarilimab program by offering clinical development and commercialization benefit...
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
August 29, 2023
Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable